Oligonucleotide (siRNA) · Gene silencing: transthyretin (TTR) · developed by ALNYLAM PHARMACEUTICALS
ALN-TTRSC04 is a small interfering RNA administered by subcutaneous injection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05661916 | Phase 1 | Transthyretin-Mediated Amyloidosis | Completed | ALNY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Transthyretin-Mediated Amyloidosis
Updated Oct 11, 2026. Something wrong or missing? Report it on the ALNY page.
See ALNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ALNY catalysts and pipeline →